NCT05076812

Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 96 (estimated)
• Sponsor: Sohag University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects

Detailed description

this case control study will measure plasma level of interleukin 38 in 4 groups of 24 subject, group one will have psoriatic patients, group 2 will have psoriatic patients with metabolic syndrome, group three will have patients with metabolic syndrome only, and group 4 will have healthy control subjects.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	measure plasma level of interleukin 38 by ELISA kit	draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test

Timeline

• Start date: 2021-10-01
• Primary completion: 2022-05-01
• Completion: 2022-12-01
• First posted: 2021-10-13
• Last updated: 2021-10-21